Additional file 5 of Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

Additional file 5: Supplementary Fig. 5. LNK-754 and lonafarnib increase total LAMP1 levels in the brains of 5XFAD mice. A Immunoblot of brain homogenates from vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for LAMP1 and actin. Quantifications of LAMP1 (B) immunoblots in (A). Signals were normalized to actin and expressed as fold of vehicle (***p = 0.0009 between vehicle and LNK-754, ****p < 0.0001 between vehicle and lonafarnib). Quantification of total LAMP1 fluorescence intensity levels, shown in Fig. 2A and B, in the cortex (*p = 0.029 between vehicle and LNK-754, *p = 0.026 between vehicle and lonafarnib) (C) and hippocampus (**p = 0.0054 between vehicle and LNK-754, *p = 0.011 between vehicle and lonafarnib) (D) of vehicle, LNK-754 and lonafarnib treated 5XFAD mice. Quantification of dystrophic neurite LAMP1 fluorescence intensity levels, shown in Fig. 2A and B, in the cortex (E) and hippocampus (F) of vehicle, LNK-754 and lonafarnib treated 5XFAD mice. Vehicle, n = 11 (5 males, 6 females); LNK-754, n = 10 (4 males, 6 females); lonafarnib n = 10 (4 males, 6 females). Triangles represent males and circles represent females. 1-way ANOVA with Tukey’s post-hoc multiple comparisons test was performed.